Autopsy report · NCT06279195

Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment

“Could not obtain approval for the planned study with available funding”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Endeavor Health

Sponsor type

University, hospital or other

Conditions

Pelvic Pain

Interventions

Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Safety & Efficacy of Intranasal Dexmedetomidine, Fentanyl & Midazolam in the Pediatric Emergency Room
  “Unable to obtain funding to initiate/complete study” (87% match in meaning)
• Augmented Reality-based Telerehabilitation Platform for Patients With Stroke
  “Study did not receive funding” (82% match in meaning)
• Study of EQU-001 for Uncontrolled Focal Onset Seizures
  “insufficient funding to complete the study” (82% match in meaning)
• L-tetrahydropalmatine (l-THP) Treatment for Cocaine Use Disorder
  “Study funding has not been established” (82% match in meaning)
• Hemp-Derived Botanical Dietary Supplementation During Recovery From Brain Injury
  “Lack of initial funding after approval of study” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.